Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZL3IV)

Drug Name

Alemtuzumab Drug Info

Synonyms

Campath (TN); MabCampath (TN); Campath-1H (TN)

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[1]
Chronic lymphocytic leukaemia	2A82.0	Approved	[2]
Immunodeficiency	4A00-4A85	Approved	[3]
Leukemia		Approved	[4]
Multiple sclerosis	8A40	Approved	[2]
Myeloproliferative neoplasm	2A20	Approved	[5]
Systemic lupus erythematosus	4A40.0	Approved	[6]
Systemic sclerosis	4A42	Approved	[7]
Neuroblastoma	2D11.2	Investigative	[8]

Therapeutic Class

Anticancer Agents

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cambridge pathology 1 antigen (CD52)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GZ402668	DME6VX4	Multiple sclerosis	8A40	Phase 1	[10]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cambridge pathology 1 antigen (CD52)	TTQT5S9	CD52_HUMAN	Not Available	[9]

------------------------------------------------------------------------------------

References

1	Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May;15(5):610-7.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6770).
3	Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. CNS Drugs. 2021 Nov;35(11):1173-1188.
4	T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment. Int J Mol Sci. 2023 Jul 28;24(15):12106.
5	Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res. 2004 Dec;28(12):1255-62.
6	Therapeutic Interventions of Tissue Specific Autoimmune Onset in Systemic Lupus Erythematosus. Mini Rev Med Chem. 2017;17(15):1418-1424.
7	Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis. Arthritis Rheumatol. 2021 Sep;73(9):1720-1730.
8	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
9	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49.
10	Characterization of a Next Generation Anti-CD52 Antibody. Neurology. April 6, 2015 vol. 84 no. 14.